FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to pharmaceutical composition for obtaining tablets, which includes in one standard form, for instance, in one tablet, the following ingredients: (a) active ingredient, such as (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidin (vildagliptin), or its pharmaceutically acceptable salt, (b) hydroxypropylmethylcellulose, whose apparent viscosity in 1% solution constitutes from 80000 cP to 120000 cP (nominal value 100000 cP), (c) microcrystalline cellulose and (d) magnesium stearate.
EFFECT: composition possesses high stability and efficiency.
35 cl, 42 tbl, 26 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| GUANFACINE-BASED PHARMACEUTICAL COMPOSITIONS, SUITABLE FOR DAILY INTRODUCTION IN FORM OF SINGLE DOSED FORM | 2006 |
|
RU2435573C2 |
| TACROLIMUS FOR IMPROVED TREATMENT OF PATIENTS WITH GRAFTS | 2009 |
|
RU2574006C2 |
| COMBINED DELIVERY SYSTEM WITH IMMEDIATE/SUSTAINED RELEASE OF MEDICINAL AGENTS WITH SHORT PERIOD OF HALF-LIFE, INCLUDING FOR REMOGLIFLOZIN | 2011 |
|
RU2596787C2 |
| MEDICINAL FORMS CONTAINING AG013736 | 2004 |
|
RU2341263C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HELICOBACTER PYLORI | 2014 |
|
RU2671400C2 |
| DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR | 2008 |
|
RU2493844C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| ORAL VILDAGLIPTIN OSMOTIC PHARMACEUTICAL COMPOSITION | 2016 |
|
RU2706706C1 |
| ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS | 2014 |
|
RU2679448C2 |
| COMBINED THERAPY WITH GPR119 AGONISTS AND DPP-4 INHIBITORS | 2020 |
|
RU2818562C2 |
